CINCINNATI, June 20, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is very pleased to announce that it has received final approval to list its common shares on the Toronto Stock Exchange (the “TSX”) and will commence trading on the TSX at market open on June 21, 2023 under the symbol “QIPT”. Concurrent with the commencement of trading on the TSX, the common shares will be delisted and will cease trading on the TSX Venture Exchange.

“We are incredibly proud to announce the commencement of trading on the Toronto Stock Exchange. This significant milestone underscores our commitment to growth and provides a strong foundation for our investors. As we work to establish ourselves as a national leader in respiratory care across the United States, our ability to list on the TSX shows the sustained expansion of our organization over the years and the ongoing momentum across the business,” said Greg Crawford, Chairman and CEO of Quipt. “We believe that this listing will provide us with increased visibility and access to a broader investor base, which will further support our mission to deliver exceptional value to our shareholders. We’re excited about this next step in our journey and are deeply appreciative of the support from our investors, our team, and the TSX.”

Shareholders are not required to exchange their share certificates or take any other action in connection with the TSX listing. There will be no change in the trading symbol or CUSIP for the common shares. In addition, the Company’s common shares will continue to trade on NASDAQ in the United States under the symbol “QIPT”.

ABOUT QUIPT HOME MEDICAL CORP.

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.

Certain statements contained in this press release constitute "forward-looking information" as such term is ‎‎‎‎defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", ‎‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect", "outlook", and similar expressions ‎‎‎as ‎they relate to the Company, including: the Company establishing itself as a national leader in respiratory care across the United States; and the Company believing that its TSX listing will provide it with ‎increased visibility and access to a broader investor base‎; are intended to ‎identify forward-looking information. All statements ‎other than statements of ‎‎historical fact may be forward-‎looking information. Such statements reflect the ‎Company's current views and ‎‎intentions with respect to future ‎events, and current information available to the ‎Company, and are subject to ‎‎certain risks, uncertainties and ‎assumptions. Many factors could ‎cause the actual ‎results, ‎performance or achievements that may be expressed ‎or implied by such forward-looking ‎information to ‎vary from ‎those described herein should one or more of these ‎risks or uncertainties materialize. ‎Examples of such ‎risk factors ‎include, without limitation: risks related to credit, market ‎‎(including equity, ‎commodity, foreign exchange and interest ‎rate), ‎liquidity, operational (including technology ‎and infrastructure), ‎reputational, insurance, strategic, ‎regulatory, legal, ‎environmental, and capital adequacy; the ‎general business ‎and economic conditions in the regions ‎in which the ‎Company operates; the ability of the ‎Company to execute on ‎key priorities, including the successful ‎completion of ‎acquisitions, business retention, and ‎strategic plans and to ‎attract, develop and retain key ‎executives; difficulty ‎integrating newly acquired businesses; ‎the ability to ‎implement business strategies and ‎pursue business opportunities; low profit ‎market segments; ‎disruptions in or ‎attacks (including cyber-attacks) on ‎the Company's information technology, ‎internet, network ‎access or other ‎voice or data communications systems or ‎services; the evolution of various types ‎of fraud or other ‎criminal ‎behavior to which the Company is exposed; the ‎failure of third parties to comply with ‎their obligations to ‎the ‎Company or its affiliates; the impact of new and ‎changes to, or application of, current ‎laws and regulations; ‎‎decline of reimbursement rates; dependence on few ‎payors; possible new drug discoveries; a ‎novel business model; ‎‎dependence on key suppliers; granting of permits ‎and licenses in a highly regulated ‎business; the overall difficult ‎‎litigation environment, including in the U.S.; ‎increased competition; changes in ‎foreign currency rates; increased ‎‎funding costs and market volatility due to ‎market illiquidity and competition for ‎funding; the availability of funds ‎‎and resources to pursue operations; ‎critical accounting estimates and changes ‎to accounting standards, policies, ‎‎and methods used by the Company; ‎the occurrence of natural and unnatural ‎catastrophic events and claims ‎‎resulting from such events; and risks ‎related to COVID-19 including various ‎recommendations, orders and ‎‎measures of governmental authorities to try ‎to limit the pandemic, including travel ‎restrictions, border closures, ‎‎non-essential business closures, quarantines, ‎self-isolations, shelters-in-place and social distancing, ‎disruptions ‎‎to markets, economic activity, financing, ‎supply chains and sales channels, and a deterioration of general ‎‎economic ‎conditions including a possible ‎national or global recession; as well as those risk factors discussed or ‎‎referred to ‎in the Company’s disclosure ‎documents filed with United States Securities and Exchange Commission ‎‎and ‎available at www.sec.gov, and with ‎the securities regulatory authorities in certain provinces of Canada and ‎‎‎available at www.sedar.com. Should any ‎factor affect the Company in an unexpected manner, or should ‎‎‎assumptions underlying the forward-looking ‎information prove incorrect, the actual results or events may differ ‎‎‎materially from the results or events predicted. ‎Any such forward-looking information is expressly qualified in its ‎‎‎entirety by this cautionary statement. Moreover, ‎the Company does not assume responsibility for the accuracy or ‎‎‎completeness of such forward-looking ‎information. The forward-looking information included in this press release ‎‎‎is made as of the date of this press ‎release and the Company undertakes no obligation to publicly update or revise ‎‎‎any forward-looking information, ‎other than as required by applicable law‎.‎

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information please visit our website at www.Quipthomemedical.com, or contact:‎

Cole Stevens
VP of Corporate Development ‎
Quipt Home Medical Corp.‎
‎859-300-6455‎
cole.stevens@myquipt.com

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.‎
‎859-300-6455‎
investorinfo@myquipt.com